###begin article-title 0
###xml 38 46 38 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRD2 Taq</italic>
Allelic and genotypic associations of DRD2 TaqI A polymorphism with heroin dependence in Spanish subjects: a case control study
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 118 122 118 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRD2</italic>
###xml 124 127 124 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Taq</italic>
Conflicting associations with heroin dependence have been found involving the A1 allele of dopamine D2 receptor gene (DRD2) TaqI A polymorphism.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 124 132 <span type="species:ncbi:9606">patients</span>
We compared two samples of unrelated Spanish individuals, all of European origin: 281 methadone-maintained heroin-dependent patients (207 males and 74 females) who frequently used non-opioid substances, and 145 control subjects (98 males and 47 females).
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 74 76 74 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 306 308 306 308 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 416 421 416 421 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRD2 </italic>
###xml 43 51 <span type="species:ncbi:9606">patients</span>
###xml 257 265 <span type="species:ncbi:9606">patients</span>
The A1-A1 genotype was detected in 7.1% of patients and 1.4% of controls (P = 0.011, odds ratio = 5.48, 95% CI 1.26-23.78). Although the A1 allele was not associated with heroin dependence in the entire sample, the frequency of A1 allele was higher in male patients than in male controls (24.4% vs. 16.3%, P = 0.024, odds ratio = 1.65, 95% CI 1.07-2.57). A logistic regression analysis showed an interaction between DRD2 alleles and gender (odds ratio = 1.77, 95% CI 1.15-2.70).
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 68 76 68 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRD2 Taq</italic>
Our results indicate that, in Spanish individuals, genotypes of the DRD2 TaqI A polymorphism contribute to variations in the risk of heroin dependence, while single alleles contribute only in males.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 353 354 353 354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 499 500 499 500 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 501 502 501 502 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
A better understanding of the etiology of heroin dependence is crucial for improving the prevention and treatment of this severe mental disorder. Genes that could be risk factors for heroin dependence have not been consistently identified; however, genetic epidemiology studies have shown that they do have an impact. These studies, with one exception [1], also suggest that such genetic factors are mainly nonspecific, because they also confer vulnerability to other substance use disorders (SUD) [2-4].
###end p 11
###begin p 12
###xml 46 50 46 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRD2</italic>
###xml 263 264 263 264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 265 266 265 266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 389 394 389 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRD2 </italic>
###xml 395 396 395 396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 376 380 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
The gene coding for the dopamine receptor D2 (DRD2) could be involved in heroin dependence and other SUD as a nonspecific genetic factor, because opioids and other substances of abuse induce some of their rewarding effects through the mesolimbic dopamine system [5,6]. Preclinical research supports this hypothesis. An absence of opioid-rewarding effects has been reported in mice lacking DRD2 [7].
###end p 12
###begin p 13
###xml 4 9 4 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRD2 </italic>
###xml 9 12 9 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Taq</italic>
###xml 175 176 175 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 177 179 177 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 235 237 235 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 331 333 331 333 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 475 477 475 477 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 844 845 844 845 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 846 848 846 848 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 886 888 886 888 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 344 347 <span type="species:ncbi:9606">men</span>
###xml 772 775 <span type="species:ncbi:9606">men</span>
###xml 784 789 <span type="species:ncbi:9606">women</span>
###xml 839 842 <span type="species:ncbi:9606">men</span>
###xml 881 884 <span type="species:ncbi:9606">men</span>
The DRD2 TaqI A is a SNP with two variants: A1, the less frequent allele, and A2. The A1 allele is associated with a reduction in the density of D2 receptors at the striatum [8-10], although one study failed to replicate this finding [11]. The hypofunction of D2 receptors associated with A1 allele could be a risk factor for SUD [12]. Healthy men who feel psychostimulant effects to be pleasant have lower D2 receptor availability than those who feel them to be unpleasant [13]. This result supports a model that links the A1 allele with SUD through the following sequence of facts: low D2 receptor density, moderate substance stimulation of dopamine system, and rewarding feelings after substance use. The addictive process could get started and continue more easily in men than in women, because D2 receptor density is lower in healthy men [9,14] as well as in heroin-dependent men [15].
###end p 13
###begin p 14
###xml 87 92 87 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRD2 </italic>
###xml 149 151 149 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 276 278 276 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 279 281 279 281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 303 305 303 305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 306 308 306 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 397 402 397 402 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRD2 </italic>
A series of meta-analyses performed on 55 studies has shown an association between the DRD2 A1 allele and SUD in Caucasian and non-Caucasian groups [16]. However, in the particular case of opioid use disorders, associations with the A1 allele have been found in some studies [17,18], but not in others [19,20]. The aim of the present study was to examine the association of heroin dependence with DRD2 A1 alleles in Spanish subjects of European origin.
###end p 14
###begin title 15
Methods
###end title 15
###begin title 16
Subjects
###end title 16
###begin p 17
###xml 210 212 210 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 518 520 518 520 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 539 544 539 544 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRD2 </italic>
###xml 123 131 <span type="species:ncbi:9606">Patients</span>
###xml 415 423 <span type="species:ncbi:9606">patients</span>
###xml 668 676 <span type="species:ncbi:9606">patients</span>
###xml 1252 1264 <span type="species:ncbi:9606">participants</span>
All subjects included in this study were unrelated and their four grandparents were Spanish, of European, non-Roma origin. Patients were in methadone maintenance for treating heroin dependence (DSM-IV: 304.02;[21]), and all of them reported heroin as their primary drug of choice. Non-opioid substance use was not an exclusion criterion in the present study for two reasons: first, because heroin-dependent Spanish patients frequently report use of alcohol, benzodiazepines, cannabis, and cocaine as a secondary drug [22]; second, because DRD2 is potentially a nonspecific genetic factor for substance abuse or dependence. Therefore, the exclusion of heroin-dependent patients who frequently use non-opioid substances would have reduced the external validity of our study, without improving its internal validity. In the present study, non-opioid substance use was defined as a regular and/or maladaptive use pattern during a lifelong cumulative period longer than a year. Control individuals were blood donors and clinical staff members, who declared that they did not suffer SUD, with the exception of nicotine dependence. The present study was approved by the IRB of Sant Pau Hospital (Barcelona), and written informed consent was obtained from all participants.
###end p 17
###begin title 18
Genotyping
###end title 18
###begin p 19
###xml 115 117 115 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 238 243 238 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRD2 </italic>
###xml 243 246 243 246 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Taq</italic>
###xml 301 303 301 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 396 397 395 396 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 779 782 745 748 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Taq</italic>
###xml 51 62 <span type="species:ncbi:9606">participant</span>
A 10-ml sample of venous blood was drawn from each participant, and DNA was isolated with a salting-out procedure [23]. All allele types were determined independently by two laboratory technicians blind to subject identity. Genotyping of DRD2 TaqI A polymorphism was performed by PCR as described in [24]. PCR reactions contained 10 mM Tris-HCl (pH 9.0), 50 mM KCl, 200 muM each dNTP, 1.5 mM MgCl2, 0.2 muM of each primer and 1.25 units of Taq Polymerase (Promega) in a 25 mul volume containing 50 ng sample DNA. The reaction mixture was denatured 4 min at 94degreesC, followed by 35 cycles of 94degreesC for 30 sec, 58degreesC for 30 sec, 72degreesC for 30 sec, and a final extension of 5 min at 72degreesC. Subsequently, 10 mul of the PCR product were digested with 5 units of TaqI restriction enzyme at 65degreesC overnight. The resulting products were analysed by electrophoresis and visualised under ultraviolet light. The A1-A2 genotype is revealed by three fragments (310-bp, 180-bp and 130-bp), the A2-A2 genotype by two fragments (180-bp and 130-bp), and the A1/A1 genotype is shown by an uncleaved 310-bp fragment.
###end p 19
###begin title 20
Statistical analysis
###end title 20
###begin p 21
###xml 51 56 51 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRD2 </italic>
###xml 139 140 137 138 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 261 266 259 264 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRD2 </italic>
###xml 374 376 372 374 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
Hardy-Weinberg (HW) equilibrium was tested for the DRD2 polymorphism. Genotype distributions and allele frequencies were compared using chi2-test. Moreover, two logistic regression analyses were performed in order to examine possible interactive effects of the DRD2 alleles and genotypes with gender. All statistical tests were two-sided, and were considered significant at P < 0.05.
###end p 21
###begin title 22
Results
###end title 22
###begin p 23
###xml 93 94 93 94 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 149 151 149 151 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SD</italic>
###xml 298 299 298 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 703 705 703 705 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SD</italic>
###xml 13 21 <span type="species:ncbi:9606">patients</span>
###xml 164 172 <span type="species:ncbi:9606">patients</span>
###xml 200 208 <span type="species:ncbi:9606">patients</span>
###xml 332 340 <span type="species:ncbi:9606">patients</span>
###xml 413 421 <span type="species:ncbi:9606">patients</span>
###xml 511 519 <span type="species:ncbi:9606">patients</span>
###xml 851 859 <span type="species:ncbi:9606">patients</span>
The group of patients comprised 281 methadone-maintained heroin-dependent individuals (Table 1). Males accounted for 73.7% of this sample. The mean (SD) age of the patients was 36.4 (6.3) years. Most patients reported intravenous (IV) heroin self-administration and non-opioid substance use (Table 1). In regard to these variables, patients were comparable by gender with the only exception of cannabis use: male patients reported regular and/or maladaptive patterns of cannabis use more frequently than female patients. The control group comprised 145 subjects recruited from the general population (128 blood donors and 17 clinical staff). Males accounted for 67.6% (n = 98) of this sample. The mean (SD) age of the control subjects was 35.3 (11.2) years. There were no statistically significant differences with regard to age or gender between the patients and the controls.
###end p 23
###begin p 24
###xml 37 38 37 38 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
Features of heroin-dependent patientsa
###end p 24
###begin p 25
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a </sup>
a Values are mean +/- SD unless otherwise indicated
###end p 25
###begin p 26
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b </sup>
b Non-opioid substance use is defined as a regular and/or maladaptative pattern of non-opioid substance use during a longlife cumulative period longer than a year
###end p 26
###begin p 27
###xml 35 40 35 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRD2 </italic>
###xml 73 74 73 74 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 79 80 79 80 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 177 179 175 177 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 195 199 193 197 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P = </italic>
###xml 238 240 234 236 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 256 258 252 254 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 461 463 455 457 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 479 481 473 475 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 538 540 530 532 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 556 558 548 550 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 654 656 644 646 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 672 674 662 664 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 220 227 <span type="species:ncbi:9606">patient</span>
###xml 435 443 <span type="species:ncbi:9606">patients</span>
###xml 620 628 <span type="species:ncbi:9606">patients</span>
Allele and genotype frequencies of DRD2 polymorphism are shown in Tables 2 and 3, respectively. Genotype frequencies were in Hardy-Weinberg equilibrium in the control group (chi2 = 2.01, df = 1, P = 0.16) but not in the patient group (chi2 = 5.20, df = 1, P = 0.022), probably because, as described below, the latter group was enriched in A1-A1 homozygotes. A1 allele frequencies were not statistically significantly different between patients and controls (chi2 = 2.18, df = 1, P = 0.140). Both groups differed in genotype frequency (chi2 = 6.48, df = 2, P = 0.039). Notably, the A1-A1 genotype was detected in 7.1% of patients and 1.4% of controls (chi2 = 6.43, df = 1, P = 0.011, odds ratio = 5.48 [95% CI 1.26-23.78]).
###end p 27
###begin p 28
###xml 27 35 27 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRD2 Taq</italic>
###xml 104 105 104 105 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 72 80 <span type="species:ncbi:9606">patients</span>
Distribution of alleles of DRD2 TaqI A polymorphism in heroin-dependent patients and control individualsa
###end p 28
###begin p 29
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a </sup>
a Normalised frequencies are given in brackets
###end p 29
###begin p 30
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b </sup>
###xml 5 7 3 5 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 23 25 21 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
b chi2 = 2.18, df = 1, P = 0.140
###end p 30
###begin p 31
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c </sup>
###xml 5 7 3 5 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 23 25 21 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
c chi2 = 5.08, df = 1, P = 0.024
###end p 31
###begin p 32
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">d </sup>
###xml 5 7 3 5 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 23 25 21 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
d chi2 = 1.17, df = 1, P = 0.280
###end p 32
###begin p 33
###xml 29 37 29 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRD2 Taq</italic>
###xml 39 41 39 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A </italic>
###xml 106 107 106 107 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 74 82 <span type="species:ncbi:9606">patients</span>
Distribution of genotypes of DRD2 TaqI A polymorphism in heroin-dependent patients and control individualsa
###end p 33
###begin p 34
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a </sup>
a Normalised frequencies are given in brackets
###end p 34
###begin p 35
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b </sup>
###xml 5 7 3 5 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 23 25 21 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
b chi2 = 6.48, df = 2, P = 0.039
###end p 35
###begin p 36
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c </sup>
###xml 5 7 3 5 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 23 25 21 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
c chi2 = 8.72, df = 2, P = 0.013
###end p 36
###begin p 37
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">d </sup>
###xml 5 7 3 5 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 23 25 21 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
d chi2 = 1.64, df = 2, P = 0.440
###end p 37
###begin p 38
###xml 152 153 152 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 212 214 210 212 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 230 232 228 230 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 335 336 333 334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 381 383 377 379 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 399 401 395 397 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 89 97 <span type="species:ncbi:9606">patients</span>
###xml 287 295 <span type="species:ncbi:9606">patients</span>
Allelic and genotypic comparisons between genders showed significant differences only in patients. In this group, the frequency of the A1 allele (Table 2) was higher in males than in females (24.4% vs. 14.9%; chi2 = 5.79, df = 1, P = 0.016). However, differences between male and female patients regarding genotype distribution (Table 3) did not reach statistical significance (chi2 = 5.37, df = 2, P = 0.068). DRD2 allele and genotype frequencies, however, were not significantly different between male and female controls.
###end p 38
###begin p 39
###xml 115 116 115 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 121 122 121 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 249 251 247 249 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 267 269 265 267 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 382 387 380 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRD2 </italic>
###xml 413 414 411 412 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 502 503 500 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 627 629 623 625 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 645 647 641 643 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 744 749 740 745 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRD2 </italic>
###xml 176 183 <span type="species:ncbi:9606">patient</span>
###xml 468 475 <span type="species:ncbi:9606">patient</span>
###xml 563 570 <span type="species:ncbi:9606">patient</span>
Allelic and genotypic comparisons within gender showed statistically significant differences only in males (Tables 2 and 3). Unlike the results obtained with the whole sample, patient and control males differed in the frequency of the A1 allele (chi2 = 5.08, df = 1, P = 0.024, odds ratio = 1.65 [95% CI 1.07-2.57]). The logistic regression analysis revealed an interaction between DRD2 alleles and gender (Table 4), such that the frequency of A1 allele was higher in patient than control males (Table 2). Similarly to the results obtained with the whole sample, patient and control males differed in genotype distribution (chi2 = 8.72, df = 2, P = 0.013). In this case, the logistic regression analysis did not reveal an interactive effect of DRD2 genotypes and sex (data not shown).
###end p 39
###begin p 40
Logistic regression terms for DRD2 alleles and sex
###end p 40
###begin title 41
Discussion
###end title 41
###begin p 42
###xml 42 47 42 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRD2 </italic>
###xml 342 347 342 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRD2 </italic>
###xml 347 350 347 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Taq</italic>
###xml 421 423 421 423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 447 455 <span type="species:ncbi:9606">patients</span>
The present case-control study shows that DRD2 contributes to the variation in the risk for heroin dependence in Spanish individuals. The A1-A1 genotype was significantly associated with heroin dependence in the entire sample, while the A1 allele was associated only in males. Accordingly, the conclusion of a series of meta-analyses is that DRD2 TaqI A polymorphism is associated with SUD, particularly with severe SUD [16]. We consider that the patients in the present study suffered a severe SUD, because they had a long history (approximately10 years) of mostly IV heroin use, which was frequently combined with non-opioid substance use.
###end p 42
###begin p 43
###xml 113 115 113 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 127 129 127 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 180 182 180 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 183 185 183 185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 200 202 200 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 476 481 476 481 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRD2 </italic>
###xml 492 494 492 494 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 585 587 585 587 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 230 238 <span type="species:ncbi:9606">patients</span>
Regarding specific studies on opioid use disorders, our findings agree with two previous reports from Australia [17] and Iran [18], and disagree with two other reports from China [19,20] and Germany [20]. In the Australian study, patients were in methadone treatment and often used non-opioid substances, as in the present study. Both features could maximise a study's ability to detect genetic associations: with non-opioid substance use, because it is also related with the DRD2 A1 allele [16]; and with methadone treatment, because it can be a marker of heroin dependence severity [25].
###end p 43
###begin p 44
###xml 67 69 67 69 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 70 72 70 72 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 546 548 546 548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients who participated in the studies showing negative results [19,20] were not in methadone treatment and, in the case of the Chinese individuals, rarely used illicit non-opioid substances. However, the absence of these two features does not explain the results obtained: the reason is that in China, there was little or no availability of illicit non-opioid substances in the 1990s, and that in both China and Germany, accessibility to methadone treatment was low or absent during this period. In any case, the negative results reported by [19] could also be related with the low severity of the SUD assessed, because this research group examined associations with opioid abuse, rather than opioid dependence, as did the remaining groups.
###end p 44
###begin p 45
###xml 102 104 102 104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 552 553 552 553 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 576 577 576 577 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 77 89 <span type="species:ncbi:9606">participants</span>
In the other previous study in which genetic associations were detected, all participants were males [18]. As this study did, we found allelic and genotypic associations in our male subsample. However, the female participation in our study was useful because it indicated that the genotypic association was not gender related, whereas the allelic association was indeed male-limited. The latter association could be related to the finding that nonspecific genetic factors account for much more variance percentage of illicit opioid use in males (37%) [4] than in females (3%)[3].
###end p 45
###begin p 46
###xml 405 410 405 410 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRD2 </italic>
###xml 589 590 589 590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 613 614 613 614 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 650 655 650 655 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRD2 </italic>
###xml 690 692 690 692 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 715 717 715 717 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 117 125 <span type="species:ncbi:9606">patients</span>
###xml 234 242 <span type="species:ncbi:9606">patients</span>
###xml 698 705 <span type="species:ncbi:4097">tobacco</span>
Moreover, gender comparisons in the present study showed that cannabis use was more frequent in males than in female patients, and the same trend was found regarding alcohol use. These differences suggest that our decision to include patients who use non-opioid substances in the study maximised the odds for detecting genetic associations more in males than in females. However, associations between the DRD2 A1 allele and cannabis use disorders have not been published. Moreover, nonspecific genetic factors account for a larger fraction of the variance of cannabis use in females (59%)[3] than in males (34%) [4]. Male-limited associations of the DRD2 A1 allele with alcohol dependence [26] and tobacco smoking [27] have been reported previously.
###end p 46
###begin p 47
Finally, the present study has the following limitations:
###end p 47
###begin p 48
###xml 138 140 138 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 335 337 335 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 438 439 438 439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 444 445 444 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 893 896 893 896 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Taq</italic>
###xml 151 159 <span type="species:ncbi:9606">patients</span>
###xml 1008 1020 <span type="species:ncbi:9606">participants</span>
1) The associations found could be related more to the progression and severity of heroin dependence than vulnerability to this disorder [28], because patients had a long history of heroin use; 2) Type II error is a potential explanation for our findings, since the differences detected did not reach the significance threshold (i.e.: P < 0.008) when the Bonferroni correction was applied to the six genetic comparisons performed (Tables 2 and 3); however, type II error could occur in any direction (i.e., either A1 or A2 could have been associated with heroin use), while we found that the associated allele was A1, just as in previous reports; 3) The male-limited association of A1 allele with heroin dependence must be considered as a preliminary finding, because more males than females participated in the present study and there is no indication of gender dimorphism in regard with the TaqI A alleles in the literature; 4) The findings of the present study may not be generalizable, because all study participants belonged to the same population. Still, Spaniards are closely related to the other European populations, and one would not expect to find many differences in the genetic architecture of susceptibility to heroin use.
###end p 48
###begin title 49
Conclusion
###end title 49
###begin p 50
###xml 202 210 202 210 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRD2 Taq</italic>
###xml 321 329 321 329 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRD2 Taq</italic>
###xml 549 560 <span type="species:ncbi:9606">participant</span>
###xml 596 604 <span type="species:ncbi:9606">patients</span>
To our knowledge, this is the first study performed in Latin Europe regarding the genetic associations of heroin dependence. The study was aimed to examine the association of heroin dependence with the DRD2 TaqI A polymorphism in Spanish subjects of European origin. According with our results, the A1-A1 genotype of the DRD2 TaqI A polymorphism is associated with heroin dependence regardless of gender, while the A1 allele is associated with heroin dependence only in males. These results must be considered taking into account two aspects of the participant selection. First, heroin-dependent patients who participated in the present study were not excluded if they reported non-opioid substance use. Second, the most of cases and controls were males.
###end p 50
###begin title 51
Abbreviations
###end title 51
###begin p 52
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRD2</italic>
DRD2: dopamine D2 receptor gene
###end p 52
###begin p 53
SUD: substance use disorders
###end p 53
###begin title 54
Competing interests
###end title 54
###begin p 55
The author(s) declare that they have no competing interests.
###end p 55
###begin title 56
Authors' contributions
###end title 56
###begin p 57
JP made substantial contributions to the conception and design of the study, the interpretation of data, and drafting of the manuscript. MB made substantial contributions to the conception and design of the study, oversaw genotyping, and helped to draft the manuscript.
###end p 57
###begin p 58
JT made substantial contributions to the conception and design of the study, assisted with the analysis and interpretation of the statistical data, and revised the manuscript. NS performed the statistical analyses, contributed to the interpretation of the statistical data, and revised the manuscript. VV and FC assisted with statistical analyses, contributed to the interpretation of the statistical data, and revised the manuscript. EB and EL participated in recruiting part of subjects and phenotyping of subjects. ER performed the genotyping analyses. EA made substantial contributions to the conception of the study, and helped to draft the manuscript. All authors read and approved the final manuscript.
###end p 58
###begin title 59
Acknowledgements
###end title 59
###begin p 60
###xml 405 413 <span type="species:ncbi:9606">patients</span>
###xml 519 526 <span type="species:ncbi:558547">Gallego</span>
This research was supported by the Program on Substance Abuse of the Department of Health (Government of Catalonia), the Government Delegation for the Plan Nacional sobre Drogas (National Drug Abuse Plan) of Spain's Ministry of the Interior, and the Montserrat Montero Foundation. Thanks to the members of the Barcelona Group for Addiction Genetics because their invaluable help in recruiting part of the patients who participated in the present study. The Barcelona Group for Addiction Genetics includes: A. Marco, C. Gallego, M. Rovira and J.M. Castillejo from CAS de Nou Barris; J.M. Vazquez, C. Fos, F.J. Lopez and S. Hortigosa from CAS de Sants; Ll. Vicente, S. Martin, M. Romero and L. Rodriguez from CAS de Sarria. Thanks also to Isabel Blasquiz and Vanessa Garcia for their secretarial support.
###end p 60
###begin article-title 61
###xml 45 48 <span type="species:ncbi:9606">men</span>
Co-occurrence of abuse of different drugs in men: the role of drug-specific and shared vulnerabilities
###end article-title 61
###begin article-title 62
Familial transmission of substance use disorders
###end article-title 62
###begin article-title 63
Multivariate assessment of factors influencing illicit substance use in twins from female-female pairs
###end article-title 63
###begin article-title 64
Specificity of genetic and environmental risk factors for use and abuse/dependence of cannabis, cocaine, hallucinogens, sedatives, stimulants, and opiates in male twins
###end article-title 64
###begin article-title 65
A psychomotor stimulant theory of addiction
###end article-title 65
###begin article-title 66
Drug abuse: hedonic homeostatic dysregulation
###end article-title 66
###begin article-title 67
###xml 39 43 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
Absence of opiate rewarding effects in mice lacking dopamine D2 receptors
###end article-title 67
###begin article-title 68
Allelic association of the D2 dopamine receptor gene with receptor-binding characteristics in alcoholism
###end article-title 68
###begin article-title 69
###xml 98 103 <span type="species:ncbi:9606">human</span>
D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele
###end article-title 69
###begin article-title 70
###xml 21 26 <span type="species:ncbi:9606">human</span>
The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers
###end article-title 70
###begin article-title 71
D2 receptors binding potential is not affected by Taq1 polymorphism at the D2 receptor gene
###end article-title 71
###begin article-title 72
The D2 dopamine receptor gene as a determinant of reward deficiency syndrome
###end article-title 72
###begin article-title 73
###xml 59 65 <span type="species:ncbi:9606">humans</span>
Prediction of reinforcing responses to psychostimulants in humans by brain dopamine D2 receptor levels
###end article-title 73
###begin article-title 74
###xml 43 44 43 44 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 67 72 <span type="species:ncbi:9606">human</span>
Sex differences in extrastriatal dopamine D2-like receptors in the human brain
###end article-title 74
###begin article-title 75
###xml 45 50 <span type="species:ncbi:9606">human</span>
The genetic architecture of selection at the human dopamine receptor D4 (DRD4) gene locus
###end article-title 75
###begin article-title 76
Advances in molecular genetics and the prevention and treatment of substance misuse: Implications of association studies of the A1 allele of the D2 dopamine receptor gene
###end article-title 76
###begin article-title 77
The D2 dopamine receptor A1 allele and opioid dependence: association with heroin use and response to methadone treatment
###end article-title 77
###begin article-title 78
Association between the DRD2 A1 allele and opium addiction in the Iranian population
###end article-title 78
###begin article-title 79
###xml 69 70 69 70 <sub xmlns:xlink="http://www.w3.org/1999/xlink">A</sub>
Allelic association analysis of the dopamine D2, D3, 5-HT2A, and GABAAgamma2 receptors and serotonin transporter genes with heroin abuse in Chinese subjects
###end article-title 79
###begin article-title 80
Association of specific haplotypes of D2 dopamine receptor gene with vulnerability to heroin dependence in 2 distinct populations
###end article-title 80
###begin article-title 81
Observatorio Espanol sobre Drogas
###end article-title 81
###begin article-title 82
###xml 55 60 <span type="species:ncbi:9606">human</span>
A simple salting out procedure for extracting DNA from human nucleated cells
###end article-title 82
###begin article-title 83
PCR detection of the TaqA RFLP at the DRD2 locus
###end article-title 83
###begin article-title 84
###xml 50 58 <span type="species:ncbi:9606">patients</span>
###xml 85 93 <span type="species:ncbi:9606">patients</span>
A comparison of residential heroin detoxification patients and methadone maintenance patients
###end article-title 84
###begin article-title 85
Male limited association of the dopamine receptor D2 gene TaqI A polymorphism and alcohol dependence
###end article-title 85
###begin article-title 86
Gender-specific molecular heterosis and association studies: dopamine D2 receptor gene and smoking
###end article-title 86
###begin article-title 87
Candidate gene case-control studies
###end article-title 87

